Introduction
============

Osteoporosis is a common disease characterized by reduction in bone mineral density (BMD). Increasing age, female sex and postmenopausal status are the common causes of osteoporosis. Osteoporosis in women is mainly caused by estrogen deficiency following menopause which is a potential risk factor for bone fracture and results in rapid bone loss in postmenopausal women.[@b1-ott-11-6687],[@b2-ott-11-6687] In addition to the abovementioned information, an overdose of thyroid hormone may also negatively correlate with the BMD of the lumbar spine. Differentiated thyroid carcinoma (DTC) is the most frequently occurring endocrine cancer, and its incidence has been increasing worldwide during recent decades. DTC has a favorable long-term prognosis in general. Most patients with DTC are well managed with a combined treatment of radical surgery, radioiodine (RAI) ablation and thyroid hormone replacement with an overall good survival. Thyroid-stimulating hormone suppression (TSHS) with levothyroxine (LT~4~) is important to reduce the risk of tumor recurrence of DTC, after surgery and iodine-131 (^131^I),[@b3-ott-11-6687],[@b4-ott-11-6687] because thyroid-stimulating hormone (TSH) is a trophic hormone that can stimulate the growth of cells derived from thyroid follicular epithelium. Therefore, the recommended TSH level is below 0.1 μIU/mL or slightly below or slightly above the lower reference range according to patients' risk stratification. However, TSHS may be a potential risk factor for the cardiovascular system and BMD.[@b5-ott-11-6687]--[@b7-ott-11-6687] The negative effect of TSHS on BMD in postmenopausal women with DTC remains conflicting.[@b7-ott-11-6687]--[@b18-ott-11-6687] It is well known that the loss of BMD may correlate with the risk of fractures in postmenopausal women.[@b6-ott-11-6687],[@b7-ott-11-6687] Postmenopausal DTC patients under TSHS may have bone loss in lumbar which was investigated in the study.

Patients and methods
====================

Patients
--------

Between June 2008 and June 2016, from all the patients with DTC who were referred to our department requiring ^131^I treatment or regular follow-up, postmenopausal women with DTC were included according to the following criteria: 1) history of total thyroidectomy and ablative RAI treatment for DTC and the histological results were papillary or follicular thyroid cancer; 2) treatment with LT~4~ at suppressive doses of TSH for at least 6 months after RAI and 3) BMDs were tested at least twice (at study entry and/or one during 6--24 months prior to the study). The exclusion criteria were as follows: patients with 1) metabolic osteopathy; 2) malabsorption syndrome; 3) rheumatic disease; 4) severe liver or renal disease; 5) other malignant tumor diseases; 6) bone metastasis originated from DTC or other malignancies; 7) Grave's disease; 8) ischemic heart disease or arrhythmia and 9) the use of medications that might affect bone metabolism including estrogen, glucocorticoids, bisphosphonate, denosumab, selective estrogen receptor modulators (SERMs), teriparatide, strontium ranelate, diuretics, and lithium. This study was approved by the institutional review board of Liaocheng People's Hospital research ethics committee, and all subjects gave written informed consent.

LT~4~ treatment
---------------

All patients with DTC underwent LT~4~ treatment according to the Chinese Thyroid Association (CTA) guidelines for the initial treatment and long-term management of DTC.[@b3-ott-11-6687] The CTA guidelines recommend a similar degree of TSHS to the American Thyroid Association guidelines based on the risk stratification of DTC. Serum TSH levels of \<0.1 μIU/mL are recommended for patients with persistent disease; serum TSH levels of 0.1--0.5 μIU/mL for patients free of disease, but who originally presented with high-risk disease; and a lower TSH normal range (0.3--2.0 μIU/mL) for those patients at low risk of recurrence.[@b3-ott-11-6687]

Thyroid hormone and biochemical test
------------------------------------

TSH was measured using a time-resolved immunofluorometric assay (Anytest; SYM-BIO Lifescience Co., Ltd., Shanghai, China). The normal reference range of TSH is 0.3--4.6 μIU/mL in our laboratory. Free thyroxine (FT4) and triiodothyronine (FT3) were also analyzed using the same method as TSH with the normal reference ranges of 6.6--24.8 and 3.3--8.5 pmol/L. Patients were divided into the TSHS (median TSH \<0.3 μIU/mL) and the non-suppressed groups (median TSH \>0.3 μIU/mL). Calcium was measured by automated techniques with the normal range of 2.19--2.56 mmol/L.

Assessment of vertebral BMD
---------------------------

Areal BMD (g/cm^2^) was measured at the lumbar spine, L1 to L4, using dual-energy X-ray absorptiometry (DXA; version 13.20; enCORE™ 2009; GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) according to the manufacturer's protocol. The normative database of BMD was Asian population data provided by the manufacturer. BMDs were analyzed on the same regions of interest as those used for BMD in the lumbar spine. Subjects were measured on the same densitometer, using the same software, scan speed and technologist. Measurements of BMD were performed at baseline and 6 months for all subjects; 12- and 24-month follow-ups may also be performed in the majority of patients.

Statistical analyses
--------------------

Values with normal distributions were expressed as mean ± SD. To analyze the significance of intergroup differences, the chi-squared test was used for categorical data and the unpaired or paired *t*-test was used for continuous variables. Paired *t*-test was used to compare the BMD at baseline and follow-up. The correlation of BMD with FT3 and FT4 was performed by Pearson analysis.

Results
=======

Patients' clinical characteristics
----------------------------------

Out of 232 postmenopausal DTC patients treated in our hospital, seven patients were excluded for the following: bone metastases of DTC in four patients and bisphosphonate treatment for osteoporosis in three patients. Finally, 225 patients met the inclusion criteria and were included. One hundred and fifty-four patients were in the TSHS group, and 71 patients were in the non-suppressed TSH group (control group). The serum TSH was significantly lower in TSHS patients (0.09±0.01) than that in non-suppressed patients (0.63±0.08). The other baseline characteristics of the patients in the two groups were comparable ([Table 1](#t1-ott-11-6687){ref-type="table"}). Thyroid cancers included 211 papillary carcinomas and 14 follicular carcinomas. Most of the included patients were employees. (157/225, 70%). DTC patients with TSHS (n=154) had T1N1M0 (n=25), TxN0-1M1 (n=40), T2N0-1M0 (n=28), T3N0-1M0 (n=36) and T4N0-1M0-1 (n=25; lung metastases). In 71 people in the control group, 16 had T1N0-1M0, 25 had TxN0-1M1, ten had T2N0-1M0, 15 had T3N0-1M0 and five had T4N0-1M0-1 (lung metastases). No nicotine abuses and chronic obstructive lung disease were found in the included patients.

The radioactivity of iodine for thyroid residual ablation was from 50 to 100 mCi according to patients' restaging after surgery. The dose of lymph node and lung metastases was 120 and 150--200 mCi, respectively. Most of the patients had one-time RAI treatment (n=128). Patients with lymph node or lung metastases received two to six times ^131^I treatment. A total of five patients with osteoporosis diagnosed at 6-, 12-and 24 month follow-up were treated with bisphosphonate and therefore were excluded.

Comparisons of BMD in the lumbar spine between TSHS and non-suppressed patients with DTC
----------------------------------------------------------------------------------------

No significant differences were found in the BMD of the lumbar spine between baseline and after 6, 12 and 24 months, pre and post treatment in TSHS patients with DTC and postmenopausal controls. The BMD (g/cm^2^) values in the TSHS (n=154) and control (n=71) groups were 1.03±0.17 and 0.98±0.16, 1.04±0.14 and 1.04±0.17, 1.03±0.15 and 1.06±0.27, respectively, at 6-, 12-and 24-month follow-up without significant difference (*t*=1.37, *P*=0.17; *t*=−0.128, *P*=0.89; *t*=−0.547, *P*=0.89; [Table 2](#t2-ott-11-6687){ref-type="table"}). Compared with pre-TSHS treatment, there was a reduction in the BMD of 1.9% in the lumbar spine at the 2-year follow-up.

Significant difference in the number of osteopenia and osteoporosis patients was found at 24 months (*χ*^2^=2.88, *P*=0.004) between the TSHS (103/152) and postmenopausal control (32/68) groups, and no significant difference in the number of osteopenia and osteoporosis patients was found at 6 months (72/154 vs 35/70, *χ*^2^=0.45, *P*=0.65) and 12 months (71/154 vs 30/69, *χ*^2^=0.36, *P*=0.72; [Table 3](#t3-ott-11-6687){ref-type="table"}).

Pearson analysis found that there was no significant correlation between BMD and FT3 (*r*=−0.054, *P*=0.437) and BMD and FT4 (*r*=0.003, *P*=0.986; [Figures 1](#f1-ott-11-6687){ref-type="fig"} and [2](#f2-ott-11-6687){ref-type="fig"}, respectively).

Discussion
==========

TSHS with LT~4~ is important to reduce the risk of tumor recurrence of DTC after surgery and ^131^I.[@b3-ott-11-6687]--[@b5-ott-11-6687] The effect of TSHS on BMD in postmenopausal patients with DTC remains conflicting and needs to be further clarified by large population. In addition, to the best of our knowledge, Chinese data have not published yet. Therefore, in the study, we evaluated the effect of TSHS on BMD in postmenopausal women with DTC.

BMD can be measured by DXA, single-photon absorptiometry, dual-photon absorptiometry, quantitative computed tomography,[@b19-ott-11-6687] ultrasound[@b20-ott-11-6687] and high-resolution peripheral quantitative computed tomography.[@b21-ott-11-6687] DXA is the most commonly used gold standard for BMD evaluation and was used in the study.[@b10-ott-11-6687],[@b22-ott-11-6687] Many factors affect BMD in DTC patients including TSHS, postmenopausal, inactive lifestyle and others. The majority of patients were retired from their work during the present study. In our study, the age- (postmenopausal women), sex- and disease-matched controls were used for comparison. Thus, the effects of estrogen deficiency and lifestyle in the present study population were negligible.

Similar to other studies which have not confirmed a negative effect of TSHS,[@b7-ott-11-6687],[@b14-ott-11-6687]--[@b18-ott-11-6687] our results found that TSHS is not a significant risk factor for bone loss in postmenopausal women with DTC after 2 years of follow-up. This finding is contrary to the results from smaller samples.[@b8-ott-11-6687],[@b10-ott-11-6687],[@b12-ott-11-6687]--[@b14-ott-11-6687],[@b23-ott-11-6687],[@b24-ott-11-6687] The suppressive doses of LT~4~ are unlikely[@b25-ott-11-6687] to affect BMD in premenopausal women but likely led to reductions in BMD for up to 10 years in postmenopausal women.[@b8-ott-11-6687] The conflicting results may be due to the different follow-up time, daily calcium intake or sunlight exposure as well as characteristics of the different control groups.[@b26-ott-11-6687] But one of the most important factors may be the different TSH levels observed in all those studies, TSH \<0.5 μIU/mL (0.005--1.5),[@b10-ott-11-6687],[@b27-ott-11-6687] TSH \<0.1 μIU/mL,[@b18-ott-11-6687] TSH 0.1--0.5 μIU/mL,[@b11-ott-11-6687] TSH \<0.01 μIU/mL,[@b9-ott-11-6687] TSH ≤ 0.03 μIU/mL,[@b1-ott-11-6687] etc. According to American Thyroid Association 2015 and Chinese guidelines 2012,[@b3-ott-11-6687],[@b4-ott-11-6687] the TSH target was kept at \<0.1 μIU/mL, 0.1--0.5 μIU/mL and 0.5--1 μIU/mL for patients with high-, intermediate- and low-risk DTC, respectively. The TSH assay reference in our laboratory was 0.3--0.5 μIU/mL, therefore TSH below 0.3 μIU/mL was regarded as the suppression group.

In agreement, our data also showed significant difference in the prevalence of osteoporosis and osteopenia at the 2-year follow-up, which may be due to the inhibitions of osteoblastogenesis,[@b15-ott-11-6687] osteoblasts' differentiation and stimulation of apoptosis of mature osteoclasts.[@b28-ott-11-6687],[@b29-ott-11-6687] TSHS may also have a differential impact on diverse bone sites. The reduction in BMD at the lumbar spine was 1.9% which was slightly lower than that reported (7%) at the 2-year follow-up and 5% at the hip.[@b30-ott-11-6687] Osteopenia was found more frequently in cortical bone than in trabecular bone.[@b31-ott-11-6687] Hyperthyroidism seems to affect the cortical bone in the hip and forearm more so than in the trabecular bone in the spine.[@b16-ott-11-6687] Increased FT4 levels within the normal range may cause deterioration in trabecular bone microarchitecture.[@b32-ott-11-6687] No significant correlation between BMD and FT3 and FT4 was found in our group. In addition, the BMD of femoral bone was not monitored in our study. The longer duration of TSHS with decreased vertebral bone strength by altering trabecular bone score (TBS) rather than BMD in postmenopausal DTC patients was observed.[@b33-ott-11-6687]

Calcium and vitamin D supplementation with 1,200 mg calcium intake per day and 0.25 μg vitamin D may prevent bone loss during the early post-thyroidectomy period which is in agreement with our study.[@b11-ott-11-6687] Long-term hyperthyroidism is an established risk of osteoporosis and fractures.[@b6-ott-11-6687],[@b7-ott-11-6687] Rosen et al[@b27-ott-11-6687] reported that bisphosphonates had a significant increase in BMD for DTC patients on TSHS. Therefore, BMD should be followed up regularly, and the bisphosphonates treatment may be indicated in DTC patients who had TSHS and osteoporosis.

Conclusion
==========

Our 2-year follow-up data indicated that TSHS had little effect on BMD in postmenopausal women with DTC. Large population with at least 5-year follow-up should be further investigated. BMD should be followed up regularly. Bisphosphonate drugs may be suggested for postmenopausal DTC women with osteoporosis at the beginning of TSHS. The limitations of the study are the retrospective design and lack of a BMD assessment in hip joint.
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![Pearson analysis found that there was no significant correlation between BMD and FT4 (*r*=0.003, *P*=0.986).\
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###### 

Patients' clinical characteristics

                     TSHS           Postmenopausal controls   *t*-value   *P*-value
  ------------------ -------------- ------------------------- ----------- -----------
                                                                          
  Number             154            71                                    
  TSH (μlU/mL)       0.09±0.01      0.63±0.08                 −10.57      0.00
  Age (years)        55.58±8.1      55.94±8.09                −0.3        0.76
  Height (cm)        161.4±5.83     161.44±5.43               −0.05       0.96
  Weight (kg)        62.81±10.75    63.03±9.79                −0.14       0.89
  Body mass index    23.51 ±3.54    23.17±4.02                0.6         0.55
  FT3 (pmol/L)       6.30±2.09      4.46±1.23                 8.36        0.00
  FT4 (pmol/L)       22.24±7.14     17.35±3.15                7.16        0.00
  Calcium (mmol/L)   2.24±0.15      2.21 ±0.17                1.26        0.21
  Vitamin D 25       24.57± 17.79   25.56± 19.44              −0.14       0.89
  BMD (g/cm^2^)      1.05±0.16      1.06±1.21                 −0.315      0.753

**Note:** Data are presented as mean ± SD unless otherwise specified.

**Abbreviations:** BMD, bone mineral density; FT3, triiodothyronine; FT4, free thyroxine; TSHS, thyroid-stimulating hormone suppression.

###### 

BMD of the lumbar spine (g/cm^2^) in DTC patients with TSHS and postmenopausal controls

  Follow-up   TSHS        Postmenopausal controls   *t*-value   *P*-value
  ----------- ----------- ------------------------- ----------- -----------
                                                                
  Baseline    1.05±0.16   1.06±1.21                 −0.315      0.753
  6 months    1.03±0.17   0.98±0.16                 1.37        0.17
  12 months   1.04±0.14   1.04±0.17                 −0.128      0.89
  24 months   1.03±0.15   1.06±0.27                 −0.547      0.59

**Notes:** TSHS and postmenopausal controls: baseline vs 6 months, *t*=1.209, *P*=0.228; *t*=2.018, *P*=0.05; baseline vs 12 months: *t*=0.602, *P*=0.55; *t*=0.42, *P*=0.67; baseline vs 24 months: *t*=0.97, *P*=0.33; *t*=0.004, *P*=0.997. Data are presented as mean ± SD.

**Abbreviations:** BMD, bone mineral density; DTC, differentiated thyroid carcinoma; TSHS, thyroid-stimulating hormone suppression.

###### 

The number of osteopenia and osteoporosis in DTC patients with TSHS and postmenopausal controls during the 2-year follow-up

                                                         Total   Number of osteopenia   Number of osteoporosis   *χ*^2^   *P*-value
  ------------------------------------------------------ ------- ---------------------- ------------------------ -------- -----------
                                                                                                                          
  **TSHS**                                                                                                                
                                                                                                                          
  Baseline                                               154     57                     8                                 
  6 months                                               154     66                     12                       1.48     0.14
  12 months                                              154     60                     11                       0.69     0.49
  24 months[a](#tfn5-ott-11-6687){ref-type="table-fn"}   152     90                     13                       4.3      \<0.0001
                                                                                                                          
  **Postmenopausal controls**                                                                                             
                                                                                                                          
  Baseline                                               71      23                     7                                 
  6 months                                               70      27                     8                        0.92     0.36
  12 months                                              69      22                     8                        0.07     0.94
  24 months                                              68      23                     9                        0.41     0.68

**Notes:**

Significant difference in the number of osteopenia and osteoporosis patients at 24 months (*χ*^2^=2.88, *P*=0.004) between the TSHS and postmenopausal control groups; no significant difference in the number of osteopenia and osteoporosis patients at 6 and 12 months.

**Abbreviations:** DTC, differentiated thyroid carcinoma; TSHS, thyroid-stimulating hormone suppression.
